All In Biotech

Drug Trial Radar · NCT00283686

HALT Progression of Polycystic Kidney Disease Study A

Last checked: Nov 19, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 558 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

558

Actual

Start

Jan 2006

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Sponsor type
NIH
Collaborators
Boehringer Ingelheim; Merck Sharp & Dohme LLC; Polycystic Kidney Disease Foundation; University of Pittsburgh; Washington University School of Medicine
First posted
Jan 30, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 15 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two multicenter randomized clinical trials targeting different levels of kidney function: 1) early disease defined by GFR \>60 mL/min/1.73 m2 (Study A); and 2) moderately advanced disease defined by GFR 25-60 mL/min/1.73 m2 (Study B; NCT01885559). Participants will be recruited and enrolled, either to Study A or B, over the first three years. Participants enrolled in Study A will be followed for at least 5 years, while those enrolled in Study B will be followed for five-to-eight years, with the average length of follow-up being six and a half years. The two concurrent randomized clinical trials differ by eligibility criteria, interventions and outcomes to be studied.

Conditions

  • Kidney, Polycystic

Interventions

  • LisinoprilDrug

    Lisinopril titrated to 5mg, 10mg, 20mg, 40mg

  • TelmisartanDrug

    Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants

  • PlaceboDrug

    Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants

  • Standard Blood Pressure ControlOther

    Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator

  • Low Blood Pressure ControlOther

    Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study A: Percent Annual Change in Total Kidney VolumeTime frame: Baseline and 2-, 4- and 5-year follow-up

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Health Sciences Center

    Aurora, Colorado

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Tufts University-New England Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Cleveland Clinic Foundation

    Cleveland, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.